LT4084791T - Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti - Google Patents

Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti

Info

Publication number: LT4084791T
Authority: LT; Lithuania
Prior art keywords: tryptamines; treatment; specific; mood disorders; mood
Prior art date: 2020-02-18

Application number

LTEPPCT/US2021/018534T

Other languages

English (en)

Inventor

Andrew Carry KRUEGEL

Jonathan Sporn

Original Assignee

Gilgamesh Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2020-02-18

Filing date

2021-02-18

Publication date

2025-02-25

2021-02-18 Application filed by Gilgamesh Pharmaceuticals, Inc. filed Critical Gilgamesh Pharmaceuticals, Inc.

2025-02-25 Publication of LT4084791T publication Critical patent/LT4084791T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

LTEPPCT/US2021/018534T 2020-02-18 2021-02-18 Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti LT4084791T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US202062978075P	2020-02-18	2020-02-18
PCT/US2021/018534 WO2021168082A1 (en)	2020-02-18	2021-02-18	Specific tryptamines for use in the treatment of mood disorders

Publications (1)

Publication Number	Publication Date
LT4084791T true LT4084791T (lt)	2025-02-25

Family

ID=74871827

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEPPCT/US2021/018534T LT4084791T (lt)	2020-02-18	2021-02-18	Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti

Country Status (22)

Country	Link
US (4)	US20220241243A1 (lt)
EP (2)	EP4501407A3 (lt)
JP (3)	JP7242969B2 (lt)
KR (2)	KR20230124103A (lt)
CN (2)	CN115135320B (lt)
AU (2)	AU2021224899B2 (lt)
BR (1)	BR112022016382A2 (lt)
CA (1)	CA3172046A1 (lt)
DK (1)	DK4084791T3 (lt)
ES (1)	ES3014741T3 (lt)
FI (1)	FI4084791T3 (lt)
HR (1)	HRP20250148T1 (lt)
HU (1)	HUE070631T2 (lt)
IL (2)	IL301235A (lt)
LT (1)	LT4084791T (lt)
MX (2)	MX2022010082A (lt)
PL (1)	PL4084791T3 (lt)
PT (1)	PT4084791T (lt)
RS (1)	RS66496B1 (lt)
SI (1)	SI4084791T1 (lt)
SM (1)	SMT202500143T1 (lt)
WO (1)	WO2021168082A1 (lt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2020231231A1 (en) *	2019-03-07	2021-10-07	Arbormentis LLC	Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
RS66496B1 (sr) *	2020-02-18	2025-03-31	Gilgamesh Pharmaceuticals Inc	Specifični triptamini za upotrebu u lečenju poremećaja raspoloženja
CA3182156A1 (en)	2020-05-08	2021-11-11	Psilera Inc.	Novel compositions of matter and pharmaceutical compositions
IL312785A (en)	2020-05-19	2024-07-01	Cybin Irl Ltd	Denatured Tryptamine Derivatives and Methods of Use
CA3191102A1 (en) *	2020-09-01	2022-03-10	Jillian M. HAGEL	Halogenated psilocybin derivatives and methods of using
AU2022287013A1 (en) *	2021-06-02	2023-12-07	Compass Pathfinder Ltd.	Fluorinated tryptamine compounds, analogues thereof, and methods using same
WO2023034645A2 (en) *	2021-09-03	2023-03-09	Alexander Shulgin Research Institute	Asymmetric allyl tryptamines
EP4159201A1 (en)	2021-09-30	2023-04-05	Biomind Labs Inc	Encapsulated microparticles and nanoparticles of dimethyltriptamines
JP2024540030A (ja) *	2021-10-29	2024-10-31	サイレラインコーポレイテッド	修飾インドール化合物
WO2023108174A1 (en) *	2021-12-10	2023-06-15	Terran Biosciences, Inc.	Analogs of 6-methoxy- n, n-dimethyltryptamine
WO2023115167A1 (en) *	2021-12-24	2023-06-29	Psylo Pty Ltd	Compounds
US20250091993A1 (en) *	2022-01-27	2025-03-20	Terran Biosciences Inc.	Salts and solid forms of n-ethyl-2-(5-fluoro-1h-indol-3-yl)-n-methylethan-1-amine
EP4486448A1 (en)	2022-03-04	2025-01-08	Reset Pharmaceuticals, Inc.	Co-crystals or salts comprising psilocin
EP4499085A1 (en) *	2022-03-27	2025-02-05	GH Research Ireland Limited	5-methoxy-n,n-dimethyltryptamine for the treatment of social/emotional withdrawal or detachment
WO2024046837A1 (en) *	2022-08-31	2024-03-07	Cybin Irl Limited	Tryptamine compounds, compositions, and methods of use
WO2024108195A1 (en) *	2022-11-17	2024-05-23	Remedi, Inc.	Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
US12396981B2 (en)	2023-03-09	2025-08-26	William Shulman	Methods of using DMT
WO2025000051A1 (en)	2023-06-28	2025-01-02	Psylo Pty Ltd	Pyrrolopyridine compounds for the treatment of mental illnesses
WO2025000053A1 (en)	2023-06-28	2025-01-02	Psylo Pty Ltd	Compounds
US12129234B1 (en)	2023-08-03	2024-10-29	Gilgamesh Pharmaceuticals, Inc.	Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
US12157722B1 (en) *	2023-08-03	2024-12-03	Gilgamesh Pharmaceuticals, Inc.	Crystalline hydrochloride salts of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
WO2025052388A1 (en) *	2023-09-07	2025-03-13	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Psychedelic compounds, methods of their preparation and uses thereof
WO2025111597A1 (en) *	2023-11-22	2025-05-30	Gilgamesh Pharmaceuticals, Inc.	A treatment for patients with mood disorders using n-ethyl-2-(5-fluoro-1h-indol-3-yl)- n-methylethan-1-amine or a pharmaceutically acceptable salt thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB853775A (en)	1957-09-19	1960-11-09	Parke Davis & Co	Pharmaceutical compositions and methods for producing phenylcyclohexane compounds
DE1668550A1 (de)	1967-09-19	1971-07-22	Parke Davis & Co	2-Alkoxyalkylamino-2-phenylcyclohexanonverbindungen und ihre Saeure-Additionssalze und Verfahren zu ihrer Herstellung
US4065573A (en)	1976-06-03	1977-12-27	The Upjohn Company	4-Amino-4-phenylcyclohexanone ketal compositions and process of use
CA1100516A (en)	1976-06-03	1981-05-05	Daniel Lednicer	4-amino-4-arylcyclohexanones and their ketals
CA1105938A (en)	1976-06-03	1981-07-28	Daniel Lednicer	4-amino-4-arylcyclohexanone ketals
ITRM20010356A1 (it) *	2001-06-21	2002-12-23	Sigma Tau Ind Farmaceuti	"5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
NZ537770A (en)	2002-06-21	2007-03-30	Suven Life Sciences Ltd	Tetracyclic arylsulfonyl indoles having serotonin receptor affinity
PT1517909E (pt)	2002-06-21	2007-01-31	Suven Life Sciences Ltd	Novos arilcarbonilindoles tetracíclicos que possuem afinidade para o receptor de serotonina, úteis como agentes terapêuticos, processo para a sua preparação e composições farmacêuticas que os contêm
JP4455992B2 (ja)	2002-06-21	2010-04-21	スベンライフサイエンシズリミティド	治療薬剤として有用なセロトニン受容体親和性を有するアリールアルキル・インドール、その製造方法、並びにそれらを含む医薬組成物
DE10252666A1 (de)	2002-11-11	2004-08-05	Grünenthal GmbH	N-Piperidyl-cyclohexan-Derivate
DE10252667A1 (de)	2002-11-11	2004-05-27	Grünenthal GmbH	Spirocyclische Cyclohexan-Derivate
DE10360793A1 (de)	2003-12-23	2005-07-28	Grünenthal GmbH	Spirocyclische Cyclohexan-Derivate
EP1912970A2 (en)	2005-08-10	2008-04-23	Bayer Schering Pharma Aktiengesellschaft	Acyltryptophanols for fertility control
EP1956016A1 (en)	2006-12-15	2008-08-13	Bayer Schering Pharma Aktiengesellschaft	Bicyclic acyltryptophanols
WO2008071455A1 (en)	2006-12-15	2008-06-19	Bayer Schering Pharma Aktiengesellschaft	Bicyclic acyltryptophanols
PL2271613T3 (pl)	2008-03-27	2014-09-30	Gruenenthal Gmbh	Hydroksymetylocykloheksyloaminy
KR20110110297A (ko)	2009-01-09	2011-10-06	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	불소 함유 화합물 및 이의 사용방법
JP2012528120A (ja)	2009-05-27	2012-11-12	ユニヴェルシテリブルドゥブリュッセル	ミエロペルオキシダーゼ阻害３−アルキル−５−フルオロインドール誘導体
TWI582092B (zh)	2010-07-28	2017-05-11	歌林達股份有限公司	順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物
CN104276993B (zh)	2013-07-12	2019-03-15	广东东阳光药业有限公司	吲哚衍生物及其在药物上的应用
US20180021326A1 (en) *	2016-07-23	2018-01-25	Paul Edward Stamets	Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
WO2018064465A1 (en) *	2016-09-29	2018-04-05	The Regents Of The University Of California	Compounds for increasing neural plasticity
JP7273731B2 (ja) *	2017-02-09	2023-05-15	カームテック、エルエルシー	シロシビン誘導体を含む組成物及び方法
GB201808150D0 (en)	2018-05-18	2018-07-11	Small Pharma Ltd	Therapeutic compounds
GB201716942D0 (en)	2017-10-16	2017-11-29	Small Pharma Ltd	Therapeutic compounds
MA50786A (fr)	2017-10-26	2022-04-27	Blumentech S L	Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
EP3505509A1 (en)	2017-12-29	2019-07-03	Université de Liège	Methods for the preparation of arylcycloalkylamine derivatives
CN111936127A (zh)	2018-02-15	2020-11-13	国立大学法人千叶大学	炎症性疾病或骨病的预防或治疗剂及医药组合物
CN110343050B (zh)	2018-04-04	2021-09-24	上海键合医药科技有限公司	芳香类化合物及其制备方法和用途
KR102104953B1 (ko)	2018-04-17	2020-04-27	삼육대학교 산학협력단	신규 케타민 유도체 및 이의 우울증의 예방 또는 치료 용도
TW202026281A (zh)	2018-12-12	2020-07-16	西班牙商艾斯提夫製藥股份有限公司	用於治療疼痛和疼痛相關病症之新吡咯啶–2– 甲酸衍生物
AU2020231231A1 (en)	2019-03-07	2021-10-07	Arbormentis LLC	Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
KR20220131520A (ko)	2019-12-26	2022-09-28	길가메쉬 파마슈티컬스, 인코포레이티드	아릴시클로헥실아민 유도체 및 정신장애 치료에서의 이의 용도
RS66496B1 (sr) *	2020-02-18	2025-03-31	Gilgamesh Pharmaceuticals Inc	Specifični triptamini za upotrebu u lečenju poremećaja raspoloženja
CA3191102A1 (en) *	2020-09-01	2022-03-10	Jillian M. HAGEL	Halogenated psilocybin derivatives and methods of using
CN112174851A (zh)	2020-11-09	2021-01-05	广州万孚生物技术股份有限公司	一种氟胺酮半抗原、氟胺酮抗原及其制备方法和应用
CN113234036B (zh)	2021-05-12	2023-07-14	斯莱普泰(上海)生物医药科技有限公司	Nmda受体拮抗剂及其用途

2021
- 2021-02-18 RS RS20250141A patent/RS66496B1/sr unknown
- 2021-02-18 PT PT217116847T patent/PT4084791T/pt unknown
- 2021-02-18 KR KR1020237027449A patent/KR20230124103A/ko active Pending
- 2021-02-18 SI SI202130280T patent/SI4084791T1/sl unknown
- 2021-02-18 EP EP24219503.0A patent/EP4501407A3/en active Pending
- 2021-02-18 DK DK21711684.7T patent/DK4084791T3/da active
- 2021-02-18 CA CA3172046A patent/CA3172046A1/en active Pending
- 2021-02-18 ES ES21711684T patent/ES3014741T3/es active Active
- 2021-02-18 KR KR1020227028602A patent/KR102567903B1/ko active Active
- 2021-02-18 MX MX2022010082A patent/MX2022010082A/es unknown
- 2021-02-18 FI FIEP21711684.7T patent/FI4084791T3/fi active
- 2021-02-18 IL IL301235A patent/IL301235A/en unknown
- 2021-02-18 WO PCT/US2021/018534 patent/WO2021168082A1/en not_active Ceased
- 2021-02-18 HR HRP20250148TT patent/HRP20250148T1/hr unknown
- 2021-02-18 CN CN202180015399.9A patent/CN115135320B/zh active Active
- 2021-02-18 AU AU2021224899A patent/AU2021224899B2/en active Active
- 2021-02-18 LT LTEPPCT/US2021/018534T patent/LT4084791T/lt unknown
- 2021-02-18 BR BR112022016382A patent/BR112022016382A2/pt unknown
- 2021-02-18 CN CN202311299060.3A patent/CN117503759A/zh active Pending
- 2021-02-18 HU HUE21711684A patent/HUE070631T2/hu unknown
- 2021-02-18 JP JP2022549507A patent/JP7242969B2/ja active Active
- 2021-02-18 PL PL21711684.7T patent/PL4084791T3/pl unknown
- 2021-02-18 SM SM20250143T patent/SMT202500143T1/it unknown
- 2021-02-18 EP EP21711684.7A patent/EP4084791B1/en active Active
- 2021-08-17 US US17/404,923 patent/US20220241243A1/en active Pending
- 2021-10-25 US US17/510,080 patent/US11440879B2/en active Active
2022
- 2022-08-10 IL IL295536A patent/IL295536B2/en unknown
- 2022-08-16 MX MX2024006123A patent/MX2024006123A/es unknown
2023
- 2023-03-07 JP JP2023034728A patent/JP7640600B2/ja active Active
2024
- 2024-05-31 US US18/680,473 patent/US20240317683A1/en not_active Abandoned
- 2024-06-28 US US18/758,102 patent/US20240351983A1/en active Pending
2025
- 2025-02-20 JP JP2025026050A patent/JP2025071254A/ja active Pending
- 2025-02-20 AU AU2025201184A patent/AU2025201184A1/en active Pending

Also Published As

Publication number	Publication date
EP4501407A3 (en)	2025-04-23
EP4501407A2 (en)	2025-02-05
MX2022010082A (es)	2022-11-14
US20240317683A1 (en)	2024-09-26
NZ790704A (en)	2024-12-20
CN117503759A (zh)	2024-02-06
AU2021224899A1 (en)	2022-08-25
HUE070631T2 (hu)	2025-06-28
EP4084791B1 (en)	2024-12-18
BR112022016382A2 (pt)	2022-10-25
AU2021224899B2 (en)	2025-02-27
EP4084791A1 (en)	2022-11-09
US20220041551A1 (en)	2022-02-10
WO2021168082A1 (en)	2021-08-26
IL301235A (en)	2023-05-01
JP7640600B2 (ja)	2025-03-05
CN115135320B (zh)	2023-08-29
FI4084791T3 (fi)	2025-03-08
US20240351983A1 (en)	2024-10-24
SI4084791T1 (sl)	2025-04-30
RS66496B1 (sr)	2025-03-31
CA3172046A1 (en)	2021-08-26
HRP20250148T1 (hr)	2025-04-11
PT4084791T (pt)	2025-01-24
ES3014741T3 (en)	2025-04-24
JP2023504308A (ja)	2023-02-02
IL295536B1 (en)	2023-04-01
IL295536A (en)	2022-10-01
SMT202500143T1 (it)	2025-05-12
CN115135320A (zh)	2022-09-30
JP2025071254A (ja)	2025-05-02
DK4084791T3 (da)	2025-02-03
MX2024006123A (es)	2024-06-04
PL4084791T3 (pl)	2025-04-22
JP7242969B2 (ja)	2023-03-20
US11440879B2 (en)	2022-09-13
JP2023063360A (ja)	2023-05-09
IL295536B2 (en)	2023-08-01
KR20220129054A (ko)	2022-09-22
US20220241243A1 (en)	2022-08-04
KR20230124103A (ko)	2023-08-24
KR102567903B1 (ko)	2023-08-18
AU2025201184A1 (en)	2025-03-13

Publication	Publication Date	Title
LT4084791T (lt)	2025-02-25	Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti
MX2021010193A (es)	2021-09-21	Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
DK3728284T3 (da)	2024-10-28	19-homo, 3.alpha.-hydroxy-steroid-20-on forbindelser til behandling af cns-lidelser
HUE064141T2 (hu)	2024-02-28	Azolopirimidin rákkal összefüggõ rendellenességek kezelésére
GEP20247593B (en)	2024-02-12	Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
HUE059559T2 (hu)	2022-12-28	5HT agonisták az epilepsziás rendellenességek kezelésére
EA201990001A1 (ru)	2019-05-31	Новые гетероциклические производные, применимые в качестве ингибиторов shp2
CY1117317T1 (el)	2017-04-26	Αναστολεις κινασης janus για θεραπεια ξηροφθαλμιας και αλλων σχετικων με τον οφθαλμο ασθενειων
MX383652B (es)	2025-03-14	Moduladores de la vía de estrés integrada.
EA201890185A1 (ru)	2018-07-31	Способы лечения опосредованных гепсидином нарушений
HUE050155T2 (hu)	2020-12-28	1-tetrahidropiranilkarbonil-2,3-dihidro-1H-indol vegyületek rák kezelésére
EA201792604A1 (ru)	2018-04-30	Ингибиторы аутотаксина и их применения
EA201892008A1 (ru)	2019-06-28	Соединения и способы лечения неврологических и сердечно-сосудистых состояний
HUE052187T2 (hu)	2021-04-28	Helyettesített pirido[3,4-b]indolok porcrendellenességek kezelésére
MX378739B (es)	2025-03-11	Compuestos de 2-oxindol.
EA201791937A1 (ru)	2018-07-31	Противовоспалительные полипептиды
LT3532064T (lt)	2020-09-25	Kompleksiniai gydymai, apimantys imidazopirazonus, skirti psichiatrinių ir (arba) kognityvinių sutrikimų gydymui
IL313097A (en)	2024-07-01	Methods of treating cns disorders
HUE057197T2 (hu)	2022-04-28	Eljárás nafta hirdogénezõ kezelésére
LT3709996T (lt)	2024-06-25	Kumarino darinys, skirtas ląstelių proliferacijos sutrikimo terapijai arba profilaktikai
HUE048750T2 (hu)	2020-08-28	(R)-3-((3S,4S)-3-fluor-4-(4-hidroxifenil)piperidin-l-il)-l-(4-metilbenzil)pirrolodin-2-on és prodrugjai pszichiátriai rendellenességek kezelésére
IT201700104446A1 (it)	2019-03-19	Compositions, uses and methods for treatment of infertility and subfertility
IL308669A (en)	2024-01-01	Methods of treating mitochondria-related disorders
LT3448382T (lt)	2021-04-12	Arimoklomolis, skirtas su gliukocerebrozidaze susijusiems sutrikimams gydyti
HUE066941T2 (hu)	2024-09-28	Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére